Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is associated with
substantial morbidity, mortality, and healthcare use. Great strides have been made in stroke …

Atrial fibrillation (AF) is an arrhythmia that can occur as the result of numerous different
pathophysiological processes in the atria. Some aspects of the morphological and …

The Japanese Circulation Society (JCS) published the “Guidelines for Pharmacological
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …

Hypertension and atrial fibrillation (AF) are 2 important public health priorities. Their
prevalence is increasing worldwide, and the 2 conditions often coexist in the same patient …

Recommendations about therapy for hypertension are here preceded by some
considerations on the strength of available evidence on the benefits associated with …

1.1. Organization of Committee and Evidence Review (UPDATED) For new or updated text,
view the 2011 Focused Update and the 2011 Update on Dabigatran. Text supporting …

The present guidelines are a revision of the 2008 version of Guidelines for
Pharmacotherapy of Atrial Fibrillation, 1 which were originally published in 2001, 2 and …

in patients with diastolic dysfunction. In a prospective study of 344 patients with heart failure
and sinus rhythm, the onset of AF was associated with highly significant worsening of the …

Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance, increasing
in prevalence with age. AF is often associated with structural heart disease, although a …

Atrial fibrillation (AF) is one of the most common arrhythmias encountered in clinical practice.
AF is a major risk factor for stroke, which is associated with high mortality and great disability …